Mometasone furoate nasal spray provides early, continuing relief of nasal congestion and improves nasal patency in allergic patients

American Journal of Rhinology and Allergy

Volumn 24, Issue 6, 2010, Pages 433-438

  Salapatek, Anne Marie ^a   Patel, Piyush ^a   Gopalan, Gokul ^b   Varghese, Santosh T ^b  

^a Cetero Research   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOMETASONE FUROATE; NOSE SPRAY; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NOSE CONGESTION; PATIENT COMPLIANCE; POLLEN ALLERGY; QUALITY OF LIFE; QUESTIONNAIRE; RAGWEED POLLEN; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS QUALITY OF LIFE QUESTIONNAIRE; SCORING SYSTEM; SORE THROAT; TOTAL NASAL SYMPTOM SCORE; TREATMENT OUTCOME;

ADULT; AGED; AMBROSIA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NASAL OBSTRUCTION; NASAL SPRAYS; PREGNADIENEDIOLS; QUALITY OF LIFE; RHINOMETRY, ACOUSTIC;

EID: 78649944845     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2010.24.3548     Document Type: Article

References (28)

1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 Update. Allergy 63(suppl 86):8-160, 2008.
2. Gawchik S, Goldstein S, Prenner B, and John A. Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. Ann Allergy Asthma Immunol 90:416-421, 2003. (Pubitemid 36459047)
3. Hebert JR, Nolop K, and Lutsky BN. Once-daily mometasone furoate aqueous nasal spray (Nasonex™) in seasonal allergic rhinitis: An active- and placebo-controlled study. Allergy 51:569-576, 1996. (Pubitemid 26276133)
4. Schenkel E, LaForce C, and Gates D. Mometasone furoate nasal spray in seasonal allergic rhinitis: Effective in relieving ocular symptoms. Allergy Clin Immunol Int - J World Allergy Org 19:50-53, 2007.
5. Bielory L. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Allergy Asthma Immunol 100:272-279, 2008. (Pubitemid 351398007)
6. Anolik R; for the Mometasone Furoate Nasal Spray With Loratadine Study Group. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 100:264-271, 2008.
7. Anolik R, Pearlman D, Teper A, and Gates D. Mometasone furoate improves nasal and ocular symptoms of seasonal allergic rhinitis in adolescents. Allergy Asthma Proc 30:406-412, 2009.
8. Berger WE, Nayak AS, and Staudinger HW. Mometasone furoate improves congestion in patients with moderate-to-severe seasonal allergic rhinitis. Ann Pharmacother 39:1984-1989, 2005.
9. Mandl M, Nolop K, Lutsky B, and the 194-079 Study Group. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. Ann Allergy Asthma Immunol 79:370-345, 1997.
10. Nathan RA, Eccles R, Howarth PH, et al. Objective monitoring of nasal patency and nasal physiology in rhinitis. J Allergy Clin Immunol 115:S442-S459, 2005. (Pubitemid 40320995)
11. Terheyden H, Maune S, Mertens J, and Hilberg O. Acoustic rhinometry: Validation by three-dimensionally reconstructed computer tomographic scans. J Appl Physiol 89:1013-1021, 2000. (Pubitemid 32125400)
12. Hilberg O. Objective measurement of nasal airway dimensions using acoustic rhinometry: Methodological and clinical aspects. Allergy 57(suppl 70):5-39, 2002. (Pubitemid 35252364)
13. Wandalsen GF, Mendes AI, and Solé D. Objective improvement in nasal congestion and nasal hyperreactivity with use of nasal steroids in persistent allergic rhinitis. Am J Rhinol Allergy 24:e32-e36, 2010.
14. Patel D, Garadi R, Brubaker M, et al. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: Olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc 28:592-599, 2007.
15. Krug N, Loedding H, Hohlfeld JM, et al. Validation of an environmental exposure unit for controlled human inhalation studies with grass pollen in patients with seasonal allergic rhinitis. Clin Exp Allergy 33:1667-1674, 2003.
16. Day JH, Ellis AK, Rafeiro E, et al. Experimental models for the evaluation of treatment of allergic rhinitis. Ann Allergy Asthma Immunol 96:263-278, 2006. (Pubitemid 43277164)
17. Katial RK, Salapatek AM, and Patel P. Establishing the onset of action of intranasal corticosteroids: Is there an ideal study design? Allergy Asthma Proc 30:595-604, 2009.
18. Salapatek A, Patel P, Chan K, et al. An environmental exposure chamber specific rhinoconjunctivitis quality of life questionnaire: The symptoms of seasonal allergic rhinitis correlate with the quality of life of patients with ragweed allergy in the chamber. Allergy 62(suppl 83):118 2007.
19. Sauve H, Patel P, Juniper E, and Talwar, N. Development plan for a rhinoconjunctivitis quality of life questionnaire in an environmental exposure chamber setting. Poster presented at XXV Congress of the European Academy of Allergology and Clinical Immunology, Vienna, Austria, June 13, 2006.
20. Guidance for Industry. Allergic rhinitis: Clinical development programs for drug products. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD. April 2000.
21. Committee for Medicinal Products for Human Use. Guidelines on the clinical development of medicinal products for the treatment of allergic rhinoconjunctivitis. Committee for Medicinal Products for Human Use, European Medicines Agency, London, U.K., October 21, 2004.
22. A landmark survey of nasal allergy sufferers: Executive summary: Adult. Available online at www.mmcpub.com/scsaia/AdultSummary.pdf; last accessed July 6, 2010.
23. Wang DY, Raza MT, Goh DYT, et al. Acoustic rhinometry in nasal allergen challenge study: Which dimensional measures are meaningful? Clin Exp Allergy 34:1093-1098, 2004.
24. Wilson AM, Sims EJ, Orr LC, et al. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 87:344-349, 2001.
25. Oztürk F, Türktaçs I, Asal K, et al. Effect of intranasal triamcinolone acetonide on bronchial hyper-responsiveness in children with seasonal allergic rhinitis and comparison of perceptional nasal obstruction with acoustic rhinometric assessment. Int J Pediatr Otorhinolaryngol 68:1107-1115, 2004. (Pubitemid 38979831)
26. Hilberg O, and Pedersen OF. Acoustic rhinometry: Recommendations for technical specifications and standard operating procedures. Rhinology 16(suppl):3-17, 2000. (Pubitemid 32015840)
27. Lenders H, and Pirsig W. Diagnostic value of acoustic rhinometry: Patients with allergic and vasomotor rhinitis compared with normal controls. Rhinology 28:5-16, 1990. (Pubitemid 20112584)
28. Varghese S, et al. Duration of action of mometasone furoate nasal spray in subjects with symptoms of seasonal allergic rhinitis induced in an environmental exposure chamber. Poster presented at 2008 AAAAI Annual meeting. Philadelphia, Pennsylvania, March 14-18, 2008.